抗结核药物致超敏反应:临床特点及危险因素。

IF 2.1 4区 医学 Q3 ALLERGY
Allergologia et immunopathologia Pub Date : 2025-09-01 eCollection Date: 2025-01-01 DOI:10.15586/aei.v53i5.1427
Zeynep Yegin Katran, İsmet Bulut, Aylin Babalık, Metin Keren, Fatma Merve Tepetam
{"title":"抗结核药物致超敏反应:临床特点及危险因素。","authors":"Zeynep Yegin Katran, İsmet Bulut, Aylin Babalık, Metin Keren, Fatma Merve Tepetam","doi":"10.15586/aei.v53i5.1427","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Antituberculosis drugs can cause hypersensitivity reactions that interrupt treatment and increase morbidity. Early identification and management are essential to prevent complications and drug resistance.</p><p><strong>Objective: </strong>To evaluate the clinical characteristics, risk factors, and outcomes of antituberculosis drug-induced hypersensitivity reactions over a 10-year period in a tertiary referral center.</p><p><strong>Methods: </strong>We retrospectively analyzed 449 patients hospitalized for antituberculosis drug-induced hypersensitivity between 2015 and 2024. A control group of 478 tuberculosis patients without hypersensitivity was included. Demographic features, comorbidities, hypersensitivity types, causative drugs, and treatment outcomes were compared.</p><p><strong>Results: </strong>The prevalence of hypersensitivity was 12.1%. Female gender, older age, Turkish nationality, and history of other drug allergies were significant risk factors. Type 1 reactions (77.7%) were more common and associated with shorter treatment interruption and higher cure rates. Pyrazinamide was the most frequently implicated drug. Desensitization was successful in the majority of patients.</p><p><strong>Conclusion: </strong>This large cohort study highlights key risk factors and clinical outcomes in tuberculosis drug hypersensitivity. Close monitoring of high-risk patients in the early treatment phase may reduce delays and improve outcomes.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 5","pages":"69-77"},"PeriodicalIF":2.1000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Antituberculosis drug-induced hypersensitivity: clinical characteristics and risk factors.\",\"authors\":\"Zeynep Yegin Katran, İsmet Bulut, Aylin Babalık, Metin Keren, Fatma Merve Tepetam\",\"doi\":\"10.15586/aei.v53i5.1427\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Antituberculosis drugs can cause hypersensitivity reactions that interrupt treatment and increase morbidity. Early identification and management are essential to prevent complications and drug resistance.</p><p><strong>Objective: </strong>To evaluate the clinical characteristics, risk factors, and outcomes of antituberculosis drug-induced hypersensitivity reactions over a 10-year period in a tertiary referral center.</p><p><strong>Methods: </strong>We retrospectively analyzed 449 patients hospitalized for antituberculosis drug-induced hypersensitivity between 2015 and 2024. A control group of 478 tuberculosis patients without hypersensitivity was included. Demographic features, comorbidities, hypersensitivity types, causative drugs, and treatment outcomes were compared.</p><p><strong>Results: </strong>The prevalence of hypersensitivity was 12.1%. Female gender, older age, Turkish nationality, and history of other drug allergies were significant risk factors. Type 1 reactions (77.7%) were more common and associated with shorter treatment interruption and higher cure rates. Pyrazinamide was the most frequently implicated drug. Desensitization was successful in the majority of patients.</p><p><strong>Conclusion: </strong>This large cohort study highlights key risk factors and clinical outcomes in tuberculosis drug hypersensitivity. Close monitoring of high-risk patients in the early treatment phase may reduce delays and improve outcomes.</p>\",\"PeriodicalId\":7536,\"journal\":{\"name\":\"Allergologia et immunopathologia\",\"volume\":\"53 5\",\"pages\":\"69-77\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Allergologia et immunopathologia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.15586/aei.v53i5.1427\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergologia et immunopathologia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.15586/aei.v53i5.1427","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:抗结核药物可引起超敏反应,中断治疗并增加发病率。早期识别和管理对于预防并发症和耐药至关重要。目的:评价某三级转诊中心10年来抗结核药物致过敏反应的临床特点、危险因素和结局。方法:回顾性分析2015 - 2024年住院的449例抗结核药物致过敏患者。对照组为478例无超敏反应的肺结核患者。比较人口统计学特征、合并症、过敏类型、致病药物和治疗结果。结果:超敏反应发生率为12.1%。女性、年龄较大、土耳其国籍和其他药物过敏史是重要的危险因素。1型反应(77.7%)更为常见,并且与较短的治疗中断和较高的治愈率相关。吡嗪酰胺是最常涉及的药物。大多数患者脱敏成功。结论:这项大型队列研究突出了结核病药物过敏的关键危险因素和临床结果。在早期治疗阶段密切监测高危患者可以减少延误并改善结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Antituberculosis drug-induced hypersensitivity: clinical characteristics and risk factors.

Background: Antituberculosis drugs can cause hypersensitivity reactions that interrupt treatment and increase morbidity. Early identification and management are essential to prevent complications and drug resistance.

Objective: To evaluate the clinical characteristics, risk factors, and outcomes of antituberculosis drug-induced hypersensitivity reactions over a 10-year period in a tertiary referral center.

Methods: We retrospectively analyzed 449 patients hospitalized for antituberculosis drug-induced hypersensitivity between 2015 and 2024. A control group of 478 tuberculosis patients without hypersensitivity was included. Demographic features, comorbidities, hypersensitivity types, causative drugs, and treatment outcomes were compared.

Results: The prevalence of hypersensitivity was 12.1%. Female gender, older age, Turkish nationality, and history of other drug allergies were significant risk factors. Type 1 reactions (77.7%) were more common and associated with shorter treatment interruption and higher cure rates. Pyrazinamide was the most frequently implicated drug. Desensitization was successful in the majority of patients.

Conclusion: This large cohort study highlights key risk factors and clinical outcomes in tuberculosis drug hypersensitivity. Close monitoring of high-risk patients in the early treatment phase may reduce delays and improve outcomes.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.70
自引率
0.00%
发文量
131
审稿时长
6-12 weeks
期刊介绍: Founded in 1972 by Professor A. Oehling, Allergologia et Immunopathologia is a forum for those working in the field of pediatric asthma, allergy and immunology. Manuscripts related to clinical, epidemiological and experimental allergy and immunopathology related to childhood will be considered for publication. Allergologia et Immunopathologia is the official journal of the Spanish Society of Pediatric Allergy and Clinical Immunology (SEICAP) and also of the Latin American Society of Immunodeficiencies (LASID). It has and independent international Editorial Committee which submits received papers for peer-reviewing by international experts. The journal accepts original and review articles from all over the world, together with consensus statements from the aforementioned societies. Occasionally, the opinion of an expert on a burning topic is published in the "Point of View" section. Letters to the Editor on previously published papers are welcomed. Allergologia et Immunopathologia publishes 6 issues per year and is included in the major databases such as Pubmed, Scopus, Web of Knowledge, etc.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信